Company news
Nexalin Technology, Inc. (NASDAQ:NXL) news
Nexalin Technology, Inc. news releases on 6ix. Latest, Feb 3, 2025: Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood…
Press releases — page 2
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
February 2, 2025
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
January 22, 2025
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
January 13, 2025
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
December 22, 2024
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
November 25, 2024
Nexalin Technology CEO Provides Letter to Shareholders
November 10, 2024
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
October 31, 2024
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
October 31, 2024
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
October 27, 2024
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
October 21, 2024
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
October 16, 2024
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
October 13, 2024
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
September 4, 2024
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 25, 2024
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
July 17, 2024
Nexalin Technology Announces Closing of $5.2 Million Public Offering
June 30, 2024
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
June 26, 2024
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
June 25, 2024
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
June 19, 2024
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
June 12, 2024
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
June 3, 2024
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
June 2, 2024
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
May 21, 2024
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
May 8, 2024
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
April 8, 2024
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
April 3, 2024
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
April 3, 2024
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
April 1, 2024
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
March 27, 2024
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
March 13, 2024
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
March 12, 2024
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
March 5, 2024
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
February 7, 2024
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
January 22, 2024
Nexalin Technology Unveils Next-Generation HALO™ Clarity
January 10, 2024
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
December 17, 2023
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
October 24, 2023
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
October 15, 2023
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
August 6, 2023
Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
August 2, 2023
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
July 25, 2023
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region
May 31, 2023
Nexalin Technology Provides 2022 Year-End Business Update
March 26, 2023
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
January 23, 2023
Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
November 13, 2022
Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering
September 19, 2022